In terms of human pancreatic cancer, ABT-737 and obatoclax, which inhibits Bcl-2, Bcl-xL, and Mcl-1, were shown to enhance the TRAIL sensitivity of pancreatic cancer cell lines [43, 44]. The gene discussed is TNFSF10; the disease is familial pancreatic carcinoma.